| Original language | English (US) |
|---|---|
| Pages (from-to) | E59-E63 |
| Journal | American Journal of Hematology |
| Volume | 96 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 1 2021 |
ASJC Scopus subject areas
- Hematology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia. / Arslan, Shukaib; Zhang, Jianying; Dhakal, Prajwal; Moran, Jenna; Naidoo, Nuthana; Lombardi, Jennifer; Pullarkat, Vinod; Stein, Anthony S.; Marcucci, Guido; Yaghmour, George; Bhatt, Vijaya R.; Fathi, Amir T.; Aldoss, Ibrahim.
In: American Journal of Hematology, Vol. 96, No. 3, 01.03.2021, p. E59-E63.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia
AU - Arslan, Shukaib
AU - Zhang, Jianying
AU - Dhakal, Prajwal
AU - Moran, Jenna
AU - Naidoo, Nuthana
AU - Lombardi, Jennifer
AU - Pullarkat, Vinod
AU - Stein, Anthony S.
AU - Marcucci, Guido
AU - Yaghmour, George
AU - Bhatt, Vijaya R.
AU - Fathi, Amir T.
AU - Aldoss, Ibrahim
N1 - Funding Information: A.S.S. serves on the speaker bureau for Stemline, Amgen and Celgene, and on advisory boards for Stemline and Amgen. G.M. is a member of the speakers' bureau for AbbVie and Novartis, and serves on advisory board with Janssen Pharm. V.P. has served on the advisory boards for AbbVie and Jazz Pharmaceuticals and is member of speakers' bureau for Jazz, Amgen, Novartis and AbbVie. G.Y. served on Advisory Boards for Novartis, Agios and Takeda, and speaker for Jazz Pharmaceutical, Takeda, Astellas, Alexion and BMS. V.R.B. served as consultant for Genentech, Rigel, Agios, Incyte, Omeros, Takeda, Jazz Pharmaceuticals and Partnership for health analytic research, and research funding from Abbvie, Pfizer, Incyte, Jazz, Tolero Pharmaceuticals, Inc., and National Marrow Donor Program, Oncoceutics, and Novartis. A.T.F. served as consultant for Boston Biomedical, PTC Therapeutics, Agios, Celgene/Bristol‐Myers Squibb, Abbvie, Astellas, Novartis, Daiichi Sankyo, Trovagene, Seattle Genetics, Amgen, Pfizer, NewLink Genetics, Jazz, Takeda, Genentech, Blueprint, Kura Oncology, Kite, Amphivena, Trillium, Forty Seven/Gilead, and research support from Celgene/BMS, Seattle Genetics, Takeda, and Agios. I.A. has served on advisory boards with AbbVie, Amgen, KiTE pharmaceuticals, Agios, consultant for Autolus and Amgen, speaker for Jazz Pharmaceuticals. The remaining authors have no relevant conflict of interest to declare.
PY - 2021/3/1
Y1 - 2021/3/1
UR - http://www.scopus.com/inward/record.url?scp=85097309604&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097309604&partnerID=8YFLogxK
U2 - 10.1002/ajh.26057
DO - 10.1002/ajh.26057
M3 - Letter
C2 - 33227142
AN - SCOPUS:85097309604
VL - 96
SP - E59-E63
JO - American Journal of Hematology
JF - American Journal of Hematology
SN - 0361-8609
IS - 3
ER -